Citations (3)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Andrew M Evens, Kristina S Yu, Nicholas Liu, Andy Surinach, Katherine Holmes, Carlos Flores, Michelle A Fanale, Darcy R Flora & Susan K Parsons. (2024) Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study. Future Oncology 20:12, pages 749-760.
Read now
Read now
Articles from other publishers (2)
Tycel PhillipsNicholas LiuBrian BloudekKristen Migliaccio-WalleJade ReynoldsJohn M. Burke. (2023) Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States. Journal of Managed Care & Specialty Pharmacy 29:12, pages 1312-1320.
Crossref
Crossref
Chiara Vassallo, Beatrice Canali, Francesca Fiorentino, Paolo Morelli, Silvia Ripoli & Laura Fioravanti. (2023) Brentuximab vedotin + AVD in cHL: cost impact on adverse events, toxicity, second malignancies, end-of-life and subsequent lines of therapy in Italy. AboutOpen 10, pages 103-109.
Crossref
Crossref